RxDoctor Payments Data

Aden Burton

Medical · Manchester, TNNPI 1619506243

Payments from drug & device makers

$1,052in general payments, 2019–2025

Across 44 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$292
  • Novo Nordisk$180
  • AstraZeneca$116
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$106
  • Esperion Therapeutics, Inc.$105
  • Lundbeck LLC$73
  • plus $179 from 7 others

What the payments were for

  • Food & beverage$1,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,052 in reported general payments places this provider in the 60th percentile of 480 medical providers in Tennessee.

See all medical providers in Tennessee

Medicare billing

Part B allowed, 2024
$9,807
Medicare patients
39
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$55,137
FarxigaDapagliflozin Propanediol14$22,428
OzempicSemaglutide12$17,284
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,363
RizatriptanRizatriptan Benzoate17$2,513
Atorvastatin Calcium98$984
Testosterone Cypionate25$749
Albuterol Sulfate HfaAlbuterol Sulfate33$683
Omeprazole39$584
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide20$514
Pregabalin14$451
Hydroxyzine Hcl22$448
Azelastine Hcl18$400
Nebivolol Hcl14$399
SynthroidLevothyroxine Sodium11$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$116$22,42814 claims
Novo NordiskOzempic$180$17,28412 claims
AbbVieSynthroid$292$39311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 480 medical providers in Tennessee.

Other medical in Manchester

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →